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Objective: We compared 1) survival after lung transplantation of recipients of dona-
tion after cardiac death (DCD) versus brain death donor organs in the United States
and 2) recipient characteristics.
Methods: Data were obtained from the United Network for Organ Sharing for lung
transplantation from October 1987 to May 2007. Follow-up after DCD lung trans-
plantation extended to 8.6 years, median 1 year. Differences among recipients of
DCD versus brain death donor organs were expressed as a propensity score for use
in comparing risk-adjusted survival.
Results: A total of 14,939 transplants were performed, 36 with DCD organs (9 single,
27 double). Among the 36 patients, 3 have died after 1 day, 11 days, and 1.5 years.
Unadjusted survival at 1, 6, 12, and 24 months was 94%, 94%, 94%, and 87%, respec-
tively, for DCD donors versus 92%, 84%, 78%, and 69%, respectively, for brain death
donors (P5 .04). DCD recipients were more likely to undergo double lung transplan-
tation and have diabetes, lower forced 1-second expiratory volume, and longer cold
ischemic times. Once these were accounted for and propensity adjusted, survival
was still better for DCD recipients, although the P value equals .06.
Conclusion: Concern about organ quality and ischemia-reperfusion injury has limited
the application of lung DCD. However, DCD as practiced in the United States results
in survival at least equivalent to that after brain death donation. It also demonstrates
selection bias, particularly in performing double lung transplantation, making gener-
alization regarding survival difficult. Nevertheless, the data support the expanded use
of DCD.
H
ardy and colleagues1 performed the first human lung transplant in 1963, us-
ing an organ from a donor who had died of congestive heart failure. This tech-
nique of organ retrieval would now be considered DCD. The organ was
harvested after pronouncement of death in the emergency department, where the
donor had undergone closed cardiac compressions until consent was obtained from
the family.
Since then, careful definitions of brain death have been established, and almost all
solid-organ use has been restricted to donors who meet brain death criteria before
cessation of cardiac activity.2-4 However, this practice excludes patients who have
dismal prognoses butwhose condition does not fulfill the strict definitionsof braindeath.
This group of patients holds the potential to substantially increase the donor pool.5
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As the waiting list for transplantation continues to grow,
solid-organ donation using DCD has recently begun to ex-
pand, particularly for renal and hepatic transplantation.6,7
Outcomes for recipients of these DCD organs seem promis-
ing. However, the lung transplant community has been
slow to adopt DCD, primarily because of the concern that in-
creased warm ischemia might produce organ injury and graft
dysfunction. This has resulted in few publications describing
the clinical results of lung transplantation using DCD,8-12 and
no single center has a large experience. For this reason, we
queried the United Network for Organ Sharing (UNOS) reg-
istry to analyze the impact of DCD as performed in the
United States on survival after lung transplantation.
Patients and Methods
Patients
From October 1987 to April 2007, of 14,939 lung transplant reci-
pients with follow-up data, 36 underwent transplantation using
DCD at 11 centers. Recipient and donor data and duration of
follow-up for survival were obtained from the UNOS database.
Mean age of the DCD and non-DCD groups at transplant was sim-
ilar at 48 6 14 years. Two patients in the DCD group and 733
patients in the non-DCD group were children (,18 years). Mean
donor age was 326 14 years for the DCD group and 306 14 years
for the non-DCD group (Tables 1 and 2).
Follow-up
Median follow-up was 1.0 years for DCD survivors and 2.9 years for
non-DCD survivors. Ten percent of all patients were followed more
than 9 years; 10% of DCD patients were followed more than 3.9
years.
Data Analysis
Propensity score. Because DCD recipients differed from non-
DCD recipients in a number of characteristics, a propensity score
was developed using multivariable logistic regression to permit at
least limited risk adjustment of the survival comparison.13 Selection
of variables for the propensity model was based on univariable sta-
tistical significance, relevance in lung transplantation, and availabil-
ity of data (Table 3). Variables included recipient age, body mass
index, history of diabetes, chronic obstructive pulmonary disease/
emphysema diagnosis, oxygen requirement at rest, percent of pre-
dicted forced expiratory volume in 1 second, double lung transplan-
tation, organ ischemic time, and donor age. Sporadic missing values
were replaced by simple means imputation.
Survival after transplant. Unadjusted nonparametric survival
estimates were obtained using the Kaplan–Meier method. For ad-
justed patient survival, a Cox proportional hazards model was con-
structed with 2 variables: DCD donor and the propensity score.1062 The Journal of Thoracic and Cardiovascular Surgery c OData Presentation
Continuous variables are summarized by mean6 standard deviation
except for skewed variables, which are summarized by equivalent
15th, 50th (median), and 85th percentiles. Categoric data are sum-
marized by frequency and percentage. All analyses were performed
using SAS statistical software (SAS v9.1; SAS, Inc, Cary, NC).
Survival estimates and hazard ratios are accompanied by 68%
confidence limits equivalent to 61 standard error.
Results
Survival
Overall survival after lung transplantation at 1, 3, 6, 12, and
24months was 94%, 94%, 94%, 94%, and 87%, respectively,
for recipients receiving lungs from DCD donors, compared
with 92%, 88%, 84%, 78%, and 69%, respectively, for brain
TABLE 1. Population characteristics (categoric variables)
DCD
(n 5 36)
Non-DCD
(n 5 14,903)
Characteristic No. (%) No. (%) P
Recipient
Demographic
Female 19 (53) 7371 (49) .7
White 34 (94) 13,196 (89) .3
African-American 2 (5.6) 973 (6.5) .8
Diagnosis
COPD/emphysema 14 (39) 5554 (37) .8
Idiopathic pulmonary
fibrosis
1 (2.8) 2786 (19) .01
Cystic fibrosis 9 (25) 2458 (16) .2
a-1 antitrypsin deficiency 3 (8.3) 1162 (7.8) .9
Sarcoidosis 2 (5.6) 408 (2.7) .3
Bronchiectasis 1 (2.8) 300 (2.0) .7
Lymphangioleiomyomatosis 1 (2.8) 121 (0.81) .2
Crest syndrome 1 (2.8) 4 (0.027) ,.0001
Retransplant for graft
failure
3 (8.3) 38 (0.25) ,.0001
Comorbidities
History of smoking 12 (67) 1568 (61) .6
Diabetes 8 (23) 1193 (9.8) .01
Surgical
Double lung transplant 27 (75) 7263 (49) .002
Donor
Demographic
Female 18 (50) 5612 (38) .1
White 32 (89) 10,788 (72) .03
African-American 2 (5.6) 2169 (15) .1
Other 2 (5.6) 1946 (13) .2
Comorbidities
Smoking: .20 pack/y 4 (11) 3151 (25) .06
Hypertension 8 (23) 1801 (14) .2
Clinical infection 10 (29) 2849 (23) .5
Serology anti-CMV 15 (44) 8195 (57) .1
CMV, Cytomegalovirus; COPD, chronic obstructive pulmonary disease; DCD,
donation after cardiac death.ctober 2008
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DCD Non-DCD
Characteristic na
Mean 6 SD or 15th,
50th, 85th percentiles na
Mean 6 SD or 15th,
50th, 85th percentiles P
Recipient
Demographic
Age (y) 36 48 6 14 14,903 48 6 15 .9
Height (cm) 35 169 6 13 14,401 168 6 13 .8
Weight (kg) 35 67 6 20 14,401 68 6 18 .6
BMI (kg/m2) 35 23 6 4.7 14,401 24 6 4.9 .5
Pulmonary function
O2 at rest 32 2.6 6 2.2 11,270 2.7 6 2.3 .3
PCO2 31 49 6 11 8905 46 6 12 .06
FEV1 (% of predicted) 32 25 6 11 12,512 34 6 21 .09
FVC (% of predicted) 32 49 6 14 12,423 50 6 18 1
Hemodynamics
Cardiac output 21 5.8 6 1.6 8199 5.3 6 1.5 .07
PPA
Systolic 27 40 6 16 9353 42 6 19 .3
Diastolic 27 21 6 10 9218 19.5 6 10 .7
Mean 26 28 6 13 8706 28 6 13 .9
PPCW 26 15 6 9.1 8648 11 6 5.9 .02
Other
Creatinine (mg/dL) 36 0.54/0.8/1.2 12,776 0.6/0.8/1.1 .7
LAS 21 32 6 8 2468 40 6 12 .0001
Surgical
Maximum lung
ischemic time (min)
31 371 6 120 13,223 275 6 110 ,.0001
Hospital stay 33 9/17/37 8949 9/15/39 .7
Donor
Demographic
Age (y) 36 32 6 14 14,894 30 6 14 .5
Height (cm) 34 170 6 12 13,071 171 6 14 .5
Weight (kg) 34 74 6 20 13,071 72 6 17 .6
BMI (kg/m2) 34 25 6 5.6 13,071 24 6 4.6 .5
Other
Creatinine (mg/dL) 35 0.5/0.85/1.1 12,555 0.6/0.9/1.4 .01
BMI, body mass index; DCD, donation after cardiac death; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LAS, Lung allocation score;
PPA, pulmonary artery pressure; PPCW, pulmonary capillary wedge pressure; SD, standard deviation. aAvailable data.TX
death donors. DCD seemed to be associated with increased
survival (unadjusted P 5 .04, Figure 1). After adjustment
for the propensity score, the hazard ratio for DCD recipients
compared with non-DCD recipients was 0.34 (confidence
limits, 0.19–0.60; P5 .06). Non-DCD recipients had slightly
better survival immediately after transplant, but after day 20,
survival favored the DCD group. There were 2 early deaths in
the DCD group, at 1 and 11 days, and a later death at 1.5
years. Causes of death were sepsis and hepatic failure, re-
spectively, for the early deaths, and respiratory failure for
the later death.
Retransplantation
Three DCD recipients underwent subsequent retransplanta-
tion at 23 days, 3 months, and 8.5 years. Indications were pri-
mary graft dysfunction (day 23) and bronchiolitis obliterans
(3 months and 8.5 years). Actuarial freedom from retrans-
plantation was 92% (confidence limits, 85% – 96%) at
1 year. Approximately 3.2% of non-DCD recipients under-
went retransplantation within 1 day to 16 years of the primary
transplant.
Discussion
This study evaluated all DCD lung transplants performed in
the United States from 1987 to 2007. Although few have
been performed, survival was surprisingly good and similar
to or better than that for brain death donor transplantation.
There were some notable differences in donor, recipient,
and transplant characteristics between the 2 groups that
deserve mention, however.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 1063
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the brain death donor group. This may reflect 1) the increased
number of double lung transplants being performed over the
study period,14 with DCD being used more recently, or 2)
a perception that DCD organs are inferior and thus 2 lungs
might be preferable to 1 lung under these circumstances.
Some studies suggest that double lung transplant imparts
a survival advantage over single lung transplant, and the
increased use of double lung transplant may have led to
improved survival in the DCD group in our study.15-17
The second difference is the lower lung allocation score
(LAS) observed in the DCD group. In 2005, the LAS was
adopted to optimize organ use.18 In this system, a higher
LAS score reflects increased disease severity and ‘‘sickness’’
of a patient coupled with the likelihood of deriving a survival
TABLE 3. Comparison of DCD and non-DCD factors used in
propensity analyses
Factor Coefficient 6 SE P
Recipient
Age 0.03 6 0.02 .1
BMI 20.01 6 0.04 .8
Oxygen requirement 20.08 6 0.1 .5
COPD/emphysema diagnosis 0.0004 6 0.4 .9
Diabetes 1.08 6 0.4 .01
FEV1 (% of predicted) 20.03 6 0.01 .04
Double lung transplant 0.86 6 0.4 .05
Ischemic time 0.005 6 0.001 .0002
Donor
Age 0.007 6 0.01 .6
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; DCD,
donation after cardiac death; FEV1, forced expiratory volume in 1 second;
SE, standard error.
Figure 1. Overall survival stratified by mode of donation: cardiac
death versus brain death. Symbols represent deaths, vertical bars
represent 68% confidence limits, and numbers in parentheses rep-
resent patients remaining at risk. DCD, donation after cardiac
death.1064 The Journal of Thoracic and Cardiovascular Surgery c Ocbenefit with transplantation. As a generalization, sicker pa-
tients get higher allocation scores.19 The observation that
DCD recipients had lower LAS scores suggests that organs
were used on ‘‘less sick’’ patients and may reflect a bias to
use DCD organs in these patients because of perceived organ
inferiority; such patients may be better able to tolerate graft
dysfunction should it occur.
The third notable difference between the DCD and brain
death groups is the considerably longer ischemic time of
the DCD group. However, despite this known risk factor
for graft dysfunction and mortality, survival was unaf-
fected.20,21 Finally, it is interesting to note that there was
no significant difference between groups in hospital length
of stay.
Principal Findings
Survival. Survival after lung transplantation using DCD
donors in our study was excellent and, in fact, better than
survival after brain death donation. Until now, published
outcomes for DCD lung transplantation have been limited
mainly to case reports.8-11 The largest case series of DCD do-
nation previously reported (from Madrid, Spain) included 17
patients, and the results raised concern about the safety and
efficacy of DCD.12 Early mortality was high at 17%, and
1-year survival was only 69%. In our series, there were just
2 early deaths after transplantation, with 94% survival at 3
months maintained to 1 year. One explanation for the differ-
ing results may be that the techniques of DCD organ procure-
ment practiced in the Madrid series differed substantially
from those practiced in the United States. In Madrid, cardio-
pulmonary resuscitation was attempted, followed by extra-
corporeal membrane oxygenation before organ recovery
and transplantation. This technique is categorized as ‘‘uncon-
trolled’’ under the 1995 Maastricht classification system.22,23
Although the details of DCD are not specified in the UNOS
registry, we believe that all patients in this study were con-
trolled and in Maastricht category III, that is, donor treatment
was withdrawn in the intensive care unit or operating room
and organ retrieval commenced after a defined period of
cardiac standstill.
The controlled technique has many theoretic advantages,
such as preventing aspiration, minimizing warm ischemia
time, and potentially reducing ischemia-reperfusion injury.
Most programs and hospitals performing DCD specify
a time frame in which death must occur after withdrawal of
support or cancellation of procurement. Our own program
specifies that death must occur within 1 hour, although
some hospitals specify an even briefer period. In addition,
controlled DCD allows time to identify and prepare an appro-
priate recipient for transplantation. All of these aspects likely
contribute to improved survival.
This study demonstrates that DCD lung transplantation as
practiced in the controlled setting can be performed with ex-
cellent survival. These results are particularly impressivetober 2008
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that no single institution has a large experience. One would
expect some learning curve to be evident as the new tech-
nique is incorporated, but this was not demonstrated. How-
ever, generalization to uncontrolled methods of organ
procurement cannot be made.
The unadjusted survival advantage for DCD raises the
possibility that there may be some benefit to using DCD do-
nors in lung transplantation. Brain death causes inflammatory
mediator release and end-organ adhesion molecule and leu-
kocyte accumulation, as well as increased organ immunoge-
nicity in other solid-organ transplantation.24,25 Experimental
evidence in lung transplantation suggests that DCD lungs
might be less susceptible to ischemia-reperfusion injury
and in fact be preferable to brain death donation organs.26,27
Further evaluation of clinical outcomes will be necessary
before making this determination.
Retransplantation. The need for retransplantation is an
important end point to examine when comparing outcomes
after DCD versus brain death donation. Retransplantation
represents one surrogate for severe graft dysfunction in the
early postoperative period. If graft dysfunction is severe
enough, retransplantation is an option for salvage.28 Only 1
patient in this study required early retransplantation for pri-
mary graft dysfunction. The need for retransplantation also
reflects the immunologic influences of acute and chronic re-
jection.29 Two other patients required retransplantation at
later time frames, and the prevalence was higher than ob-
served after brain death donation; however, the numbers in
the DCD group were small.
Limitations
Studies using registry data have the advantage of being able
to compare survival using large numbers of patients; limita-
tions include lack of adequate data collection to establish im-
portant secondary outcomes. This study has the same
limitation, in that data were not available to adequately study
the frequency and severity of primary graft dysfunction,
rejection episodes, pulmonary function, postoperative
complications, hospital readmissions, and quality of life, all
important outcomes after lung transplantation.30 In addition,
the number of DCD donors was small and follow-up was
relatively short. However, we would expect that differences
between recipients of brain death and DCD donation would
be most evident in the early period after transplantation.
Conclusions
Our study demonstrates excellent survival and supports the
expanded use of controlled DCD for lung transplantation in
the United States.
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